Vertex, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher David Young
- Full Time Employees
- 2,000
- Sector
- Technology
- Industry
- Software - Application
- Address
- 2301 Renaissance Boulevard King of Prussia PA United States of America 19406
- IPO Date
- Jul 29, 2020
- CIK
- 0001806837
- Website
- vertexinc.com
- Similar Companies
- Business
- Vertex, Inc. is a technology company primarily engaged in providing tax compliance, tax automation, and related software solutions. The company offers a comprehensive suite of products and services including indirect tax software for managing sales and use tax, value-added tax (VAT), goods and services tax (GST), and other transactional taxes globally; automated tax determination software; tax data management solutions; cloud-based and on-premise tax compliance software; and integrated tax engines for enterprise resource planning (ERP) systems. Vertex’s product portfolio supports a range of industries including retail, manufacturing, financial services, and telecommunications, serving customers worldwide. The company also provides implementation, consulting, and support services to help businesses comply with evolving tax regulations. Founded in 1978 and headquartered in King of Prussia, Pennsylvania, Vertex operates internationally with offices and clients across North America, Europe, and Asia. Recently, Vertex has expanded its capabilities through strategic partnerships and new product launches aimed at enhancing its global tax compliance automation offerings. In the past 1-2 years, the company has focused on advancing its cloud-based tax solutions to better address digital tax complexities and cross-border tax compliance challenges. Vertex continues to invest in technology upgrades and integrations to support multinational corporations’ growing needs, positioning itself as a leader in the tax technology industry. These developments reflect Vertex’s commitment to innovation and broadening its market reach, underscoring its role in delivering advanced tax software solutions to help businesses navigate increasingly complex global tax landscapes. The company leverages its proprietary tax engine and extensive tax content database to deliver precise and scalable tax management solutions. Vertex is recognized for its strong customer support and technology-driven approach, targeting large enterprises and mid-market companies needing comprehensive tax automation and compliance tools. This dynamic business environment and Vertex’s expansions highlight the company’s strategic focus on maintaining leadership in the evolving tax technology sector through continuous product enhancement and global operational growth.
Company News
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
Vertex Delivers Enhanced Value to Customers with Vertex O Series Tax Engine for Oracle Deployed on Oracle Cloud
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
Corient Private Wealth LP Purchases 153,840 Shares of Vertex, Inc. $VERX
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Posts Positive Phase II Data on Kidney Disease Drug
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript